WTI Crude


Brent Crude


Natural Gas




Heating Oil


Rotate device for more commodity prices

Breaking News:

Nigeria Announces $41 Billion Rail Upgrade

Charles Kennedy

Charles Kennedy

Charles is a writer for Oilprice.com

More Info

How To Profit From Canada’s $22 Billion Marijuana Boom


Colorado was the first U.S. state to set up a booming legal marijuana industry a few years ago, inspiring other states to follow suit. Bit by bit, the dominoes are starting to fall and marijuana is slowly becoming more available across the country.

However, the federal government is once again hostile to marijuana – with Attorney General Jeff Sessions a particularly fierce opponent of legalization – raising questions about what comes next.

But America’s northern neighbor does not have that problem. The Canadian government is moving quickly to legalize marijuana and, unlike the patchwork state-by-state approach unfolding in the U.S., Canada is set to make it legal nationwide by this time next year.

That has kicked off speculation of a green gold rush in Canada, a market that Deloitte estimates could be worth more than $22 billion annually.

It is an investor’s dream: a market where there is huge pent up demand not currently being met, and federal legislation slated to open the flood gates. Even better, because marijuana suppliers must register and receive approval from the federal government to sell products, there are serious barriers to entry. This presents a massive case of “first-mover advantage” – the companies that get approved first will cash in on the legal marijuana bonanza.

One company in particular is poised to capture a sizable share of the market. Invictus MD (TSX:IMH.V; OTC:IVITF), a legal medical marijuana provider, is ready to hit the ground running when federal legalization passes. Here are five reasons why Invictus is a crucial company for investors to keep an eye on.

1. First-mover advantage. There are a little more than 50 licensed producers of marijuana, but Health Canada, the federal regulator, recently decided to accelerate the licensing process, recognizing that there might not be enough supply when legalization comes into effect on July 1, 2018. Invictus MD is one of these companies that has 2 of the 50 licenses in 2 major provinces, perfectly positioned to capitalize on what is largely a captive market. There are more than 400 other companies in line awaiting their licenses, but Invictus is ready to go. And there is growing speculation that suppliers will struggle to meet market demand in 2018.

2. Invictus is the first integrated marijuana-dividend stock. Invictus is the first marijuana supplier to pay a dividend to shareholders, dishing out $1 million last December. Invictus was able to do this through a series of prudent acquisitions, including upstream cultivators as well as fertilizer producers.

Last December, Invictus acquired a 33.33 percent stake in AB Laboratories Inc., a licensed producer of medical marijuana in Ontario. It also has a 33.33 percent stake in AB Ventures, which will expand Invictus’ marijuana cultivation capacity based on the 100 acres AB Ventures owns. In April, it acquired a 100 percent stake in Acreage Pharms, another licensed producer in Alberta. “With the Company’s acquisition of 100 percent of Licensed Producer Acreage Pharms in Alberta, we now have 250 acres of cultivation space that stretches from Alberta to Ontario,” Dan Kriznic, executive chairman of Invictus, said in an April statement.

In fact, Invictus (TSX:IMH.V; OTC:IVITF) has stitched together assets that make it an integrated marijuana supplier, and will benefit from selling marijuana, but also from the growth of the sector as a whole. Through the sale of fertilizers, Invictus will profit even from its competitors. As was the case with the gold rush, some of the biggest winners were the sellers of picks and shovels rather than just the explorers who found gold.

3. Market is huge. The Canadian medical marijuana market alone is worth $400 million, and growing rapidly. But that will be a small fraction of the recreational market, which will become legal in a year.

There are around 150,000 medical marijuana users, but some see the recreational market exploding to 4 million users in the first few years of legalization, with sales exceeding $8 billion annually. Deloitte says the economic impact could reach $22.6 billion – a figure larger than the wine, beer and spirits market.

When compared to the $6.7 billion size of the U.S. marijuana market, Canada’s legal marijuana market could exceed that of its much larger southern neighbor.

4. Medical marijuana companies are already exploding on the prospect of legalization. Legalization is sweeping the continent, opening up lucrative opportunities for companies that have existed for a long time by servicing the medical marijuana market. As governments relent on legalization, the valuation of medical marijuana stocks have skyrocketed. Here are the gains from 2016 for the top medical marijuana producers:

• AXIM Biotechnologies (NASDAQOTH:AXIM): exploded 1,720 percent
• Corbus Pharmaceuticals (NASDAQ:CRBP) was up 431 percent
• Aphria (NASDAQOTH:APHQF) grew 381 percent
• Aurora Cannabis (NASDAQOTH:ACBFF) was up 299 percent
• Canopy Growth Corp. (NASDAQOTH:TWMJF) up 259 percent
• Medical Marijuana (NASDAQOTH:MJNA) up 254 percent
• GW Pharmaceuticals (NASDAQ:GWPH) was up 64 percent

But the marijuana bonanza is set to continue with the recent launch of the first cannabis-based exchange-traded fund (ETF), called the Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ). The new ETF will spark a wave of investment into marijuana stocks. Invictus is included in the ETF, along with about two dozen other marijuana suppliers.

5. Top-notch management. Invictus MD is headed up by a great management team, with experience growing small companies. They have multiple strains of marijuana, ranging from pain management to cancer, epilepsy and anxiety. And, of course, the recreational sector is a massive gold mine-in- waiting. But while dozens and even hundreds of companies are rushing to build their marijuana supply chains from scratch, Invictus’ (TSX:IMH.V; OTC:IVITF) management has been carefully putting together the seeds of a hugely profitable marijuana supplier for years. Dan Kriznic, executive chairman and founder, has a track record of transforming small companies in a variety of sectors to multi-million-dollar enterprises.

The legalization of marijuana in the U.S. sparked a proliferation of suppliers and a wave of money from investors looking to cash in on the billion-dollar market that was created virtually overnight. But the Canadian market is almost unknown to many big investors, which means there is huge untapped potential for those in the know. There is no shortage of catalysts on the near-term horizon, and full legalization in Canada is a year away. Invictus is one of the few candidates set to profit from this green gold rush.

Honorable Mentions:

Corbus Pharmaceuticals (NASDAQ:CRBP): is a small-cap drug developer with a $400 million market cap. The company’s primary product is a synthetic oral endocannabinoid-mimetic – A drug that binds to the same receptors as cannabis. The drug mimics cannabinoid-based medications and has shown tremendous promise in reducing pain and inflammation.

Another biotech company which is not entirely dependent on cannabinoid-based drugs is Cara Therapeutics (NASDAQ:CARA). The company focuses primarily on pain management and pruritus. Cara Therapeutics aims to provide safe alternatives to more dangerous drugs used to treat serious problems which may prevent patients from realizing their full potential.

Zybnerba Pharmaceuticals (NASDAQ:ZYNE): is a company that is diving deep into cannabinoid therapies. Currently, the company has only two drugs in development; ZYN001 and ZYN002. ZYN001, a THC pro-drug patch, aims to treat a number of conditions through a revolutionary transdermal delivery system while ZYN002, another transdermal delivery system, this time through a gel, is the first and only synthetic non-psychoactive CBD drug of its kind. And Zynerba has the patents on both products.

AbbeVie Inc (NYSE:ABBV): is one of the few NYSE listed companies producing marijuana related products. AbbeVie’s claim to fame is their synthetic-THC drug, Marinol. The FDA-approved drug has revolutionized treatment of nausea in patients with cancer and is also prescribed to patients with AIDS suffering from appetite loss. This pharmaceutical manufacturer sells its products worldwide and will be even more appealing to investors in the coming years as positions on marijuana become more relaxed.

Astra Zeneca Plc. (NYSE:AZN): This British-Swedish Pharma giant has seen a strong run so far this year. Although Trump’s healthcare reforms have not impressed the market, analysts remain bullish on this high dividend yielding pharmaceutical giant.

By Charles Kennedy



PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. Oilprice.com, Advanced Media Solutions Ltd, it’s owners, managers, employees, and assigns (collectively “The Company”) has been paid by a third party to disseminate this communication. This compensation is a major conflict with our ability to be unbiased, more specifically:

This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. If we own any shares we will list the information relevant to the stock and number of shares here. We have been compensated by Invictus MD Strategies Corp. to conduct investor relations advertising and marketing for [TSX:IMH.V; OTC:IVITF]. Oilprice.com receives financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the company. The third party, profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which often end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, The Company often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications.

DISCLOSURE. The Company does not make any guarantee or warranty about what is advertised above. The Company is not affiliated with, any specific security. While the Company will not engage in front-running or trading against its own recommendations, The Company and its managers and employees reserve the right to hold possession in certain securities featured in its communications. Such positions will be disclosed AND will not purchase or sell the security for at least two (2) market days after publication.

NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing The Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

FORWARD-LOOKING STATEMENT. As defined in the United States Securities Act of 1933 Section 27(a), as amended in the Securities Exchange Act of 1934 Section 21(e), statements in this communication which are not purely historical are forward-looking statements and include statements regarding beliefs, plans, intent, predictions or other statements of future tense.

PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results


All trades, patterns, charts, systems, etc., discussed in this message and the product materials are for illustrative purposes only and not to be construed as specific advisory recommendations. All ideas and material presented are entirely those of the author and do not necessarily reflect those of the publisher. No system or methodology has ever been developed that can guarantee profits or ensure freedom from losses. No representation or implication is being made that using the methodology or system will generate profits or ensure freedom from losses. The testimonials and examples used herein are exceptional results, which do not apply to the average member, and are not intended to represent or guarantee that anyone will achieve the same or similar results.

AFFILIATES. Some or all of the content provided in this communication may be provided by an affiliate of The Company. Content provided by an affiliate may not be reviewed by the editorial staff member. Our affiliates may have their own disclosure policies that may differ from The Company’s policy.

TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here http://oilprice.com/terms-and-conditions If you do not agree to the Terms of Use http://oilprice.com/terms-and-conditions, please contact Oilprice.com to discontinue receiving future communications.

The information contained herein may change without notice.

Back to homepage

Leave a comment

Leave a comment

Oilprice - The No. 1 Source for Oil & Energy News